Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines

AN Venture Partners Promotes Olivia Laxton to Associate

AN Venture Partners Announces Appointment of Atsushi Shimada as Chief Technology Development Officer at Tohoku University Drug Discovery Strategy Promotion Organization

Crystalys Therapeutics Closes $130 Million Series B Funding to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout

City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics

Ken Horne of AN Venture Partners Appointed to AMED Advisory Board

AN Venture Partners Promotes Paula Schultheiss to Senior Associate

AN Venture Partners Makes New Investment in US-Based Tortugas Neuroscience

AN Venture Partners Names Two New Fellows

AN Venture Partners Announces the Addition of Yasuhiro Yamada as Advisor

Announcement of Website Relaunch

Raising the sun: Japan biotech looks to level up

S2S Japanシンポジウム、mRNA標的低分子薬や腫瘍溶解性ペプチドなど日本発シーズを紹介

AN Venture Partners to Host “S2S Japan 2025 Symposium” on November 13

Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient

AN Venture Partner’s New Portfolio Company, Crystalys Therapeutics Launches with $205M Series A Financing to Advance Next-Generation Gout Treatment

ベンチャー探訪 Pahr Therapeutics社、肺動脈性肺高血圧症にAHRを制御する治療薬を開発へ

日本発なのに米国企業へ“転生”続々、創薬スタートアップ　「100均問題」足かせ

AN Venture Partners Announces the Addition of Mikael Dolsten as Advisor